Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in its stock price following the termination of its partnership with Novo Nordisk [2][3]. Group 1: Company Actions and Events - On April 29, 2025, Hims announced a collaboration with Novo Nordisk to sell a bundled offering of Wegovy on its platform [2]. - On June 23, 2025, Novo Nordisk terminated its partnership with Hims, citing deceptive promotion and safety risks associated with Hims' products [2]. - Following the termination announcement, Hims' share price fell by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025 [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that Hims made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Specific allegations include Hims' engagement in deceptive practices regarding the sale of knockoff Wegovy versions and the risk of partnership termination with Novo Nordisk [3]. - The lawsuit claims that Hims' positive statements about its business lacked a reasonable basis due to these undisclosed risks [3].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during the specified Class Period from June 22, 2023, to June 24, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Sarepta made false and misleading statements about ELEVIDYS, which is intended for patients with Duchenne muscular dystrophy, including significant safety risks and failure to detect severe side effects [5]. - It is alleged that the adverse events from ELEVIDYS treatment would lead to a halt in recruitment and dosing in trials, attract regulatory scrutiny, and increase risks around the therapy's approvals [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record, including recovering hundreds of millions for investors [4]. - Investors are advised to select qualified legal counsel with a proven history in similar cases, as not all firms have comparable experience or resources [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7].

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Red Cat Holdings, Inc. (NASDAQ: RCAT) between March 18, 2022 and January 15, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Red Cat securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

Core Viewpoint - A securities class action lawsuit has been filed against Petco Health and Wellness Company, Inc. for allegedly making false and misleading statements regarding its business performance and growth prospects during the pandemic period [1][2]. Financial Performance - On August 24, 2023, Petco revised its FY 2023 adjusted EBITDA guidance down to a range of $460 million to $480 million from a previous range of $520 million to $540 million, and adjusted EPS guidance down to $0.24 to $0.30 from $0.40 to $0.48, citing a shift in consumer spending and pressures on discretionary business [3]. - Following the negative guidance announcement, Petco's stock price dropped by $1.35 per share, or 20.64%, closing at $5.19 per share on August 24, 2023 [3]. Legal Proceedings - The class action lawsuit covers all individuals or entities that purchased Petco securities between January 14, 2021, and June 5, 2025, and alleges that the company overstated its business model's sustainability and growth potential [1][2]. - Investors are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on August 29, 2025, to discuss their rights regarding the class action [4].

Core Points - A shareholder class action lawsuit has been filed against Petco Health and Wellness Company, Inc. alleging that the company made materially false and misleading statements regarding its business and operations [1] - The lawsuit claims that Petco's pandemic-related growth was unsustainable and that its business model focused on premium pet food was overstated [1] - Defendants are accused of downplaying the severity of issues affecting Petco's business and overstating the company's ability to achieve sustainable, profitable growth [1] Legal Information - Shareholders who purchased Petco shares between January 14, 2021, and June 5, 2025, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline to request lead plaintiff status in the lawsuit is August 29, 2025 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for investors affected by corporate misconduct [3]

NEW YORK, July 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. ("Fortrea Holdings Inc." or the "Company") (NASDAQ: FTRE) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortrea Holdings Inc. investors who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/fo ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Hims & Hers Health, Inc. common stock during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and partnerships [1][5]. Group 1: Class Action Details - The class action lawsuit is filed for purchasers of Hims common stock between April 29, 2025, and June 23, 2025, inclusive [1]. - Investors who purchased Hims stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly [3][6]. Group 2: Allegations Against Hims - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy for Hims subscribers [5]. - Specific claims include that Hims failed to disclose the nature of its collaboration with Novo, which was supposed to ensure continued access to Wegovy, and that positive statements were made about the partnership that misled investors [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Organon & Co. ("Organon" or the "Company") (NYSE: OGN) investors of a class action representing investors that bought securities between October 31, 2024 to April 30, 2025, inclusive (the "Class Period"). Organon investors have until July 22, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, b ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 30, 2025 (GLOBE NEWSWIRE) --  The Portnoy Law Firm advises DoubleVerify Holdings, Inc. ("DoubleVerify" or the "Company") (NYSE: DV) investors of a class action representing investors that bought securities between November 10, 2023 and February 27, 2025, inclusive (the "Class Period"). DoubleVerify investors have until July 21, 2025 to file a lead plaintiff motion. Investors are encouraged to contact ...

Core Viewpoint - Red Cat Holdings, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its production capacity and the value of its contracts, leading to significant stock price declines during the class period from March 18, 2022, to January 15, 2025 [1][3][4][5][6]. Group 1: Company Operations and Financial Performance - Red Cat Holdings provides products and solutions for the drone industry, including the "Teal 2" drone designed for nighttime military operations [3]. - The company overstated the production capacity of its Salt Lake City facility, claiming it could produce 1,000 drones per month, while it was only capable of producing 100 drones per month at the time of disclosure [4]. - In the first quarter of fiscal year 2025, Red Cat reported a loss of $0.17 per share, missing expectations, and generated $2.8 million in revenue, falling short by $1.07 million [5]. - The company paused manufacturing of the Teal 2 and delayed prototype builds for the U.S. Army, which directly impacted sales [5]. Group 2: Stock Price Impact - Following the disclosure of the actual production capacity on July 27, 2023, Red Cat's stock price fell nearly 9% [4]. - After the disappointing financial results reported on September 23, 2024, the stock declined over 25% [5]. - A report published by Kerrisdale Capital on January 16, 2025, questioned the feasibility of the SRR contract and led to a stock decline of more than 21% over the following two trading sessions [6].